Nintedanib in the treatment of interstitial lung disease associated with systemic sclerosis: A justified hope?

被引：0
|
作者：
Hachulla, E. [1 ]
机构：
[1] Hop Claude Huriez, Ctr Reference Malad Autoimmunes & Autoinflammatoi, Serv Med Interne & Immunol Clin, F-59037 Lille, France
来源：
REVUE DE MEDECINE INTERNE | 2019年 / 40卷 / 12期
关键词：
Nintedanib; Systemic sclerosis; Interstitial lung disease; SCLERODERMA LUNG; CONTROLLED-TRIAL; PLACEBO; CYCLOPHOSPHAMIDE;
D O I：
10.1016/j.revmed.2019.08.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：775 / 777
页数：3
相关论文
共 50 条
  • [31] Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease
    Bergamasco, Aurore
    Hartmann, Nadine
    Wallace, Laura
    Verpillat, Patrice
    CLINICAL EPIDEMIOLOGY, 2019, 11 : 257 - 273
  • [32] Systemic sclerosis-associated interstitial lung disease
    Scallan, Ciaran J.
    Collins, Bridget F.
    Raghu, Ganesh
    CURRENT OPINION IN PULMONARY MEDICINE, 2020, 26 (05) : 487 - 495
  • [33] Pathogenesis of systemic sclerosis associated interstitial lung disease
    Nihtyanova, Svetlana, I
    Denton, Christopher P.
    JOURNAL OF SCLERODERMA AND RELATED DISORDERS, 2020, 5 (2_SUPPL) : 6 - 16
  • [34] Biomarkers in Systemic Sclerosis Associated Interstitial Lung Disease
    Matson, S.
    Dvorkin, D.
    Fischer, A.
    Achtar-Zadeh, N.
    Wolters, P. J.
    Lee, J. S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [35] Systemic sclerosis-associated interstitial lung disease
    Perelas, Apostolos
    Silver, Richard M.
    Arrossi, Andrea, V
    Highland, Kristin B.
    LANCET RESPIRATORY MEDICINE, 2020, 8 (03): : 304 - 320
  • [36] Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial
    Kuwana, Masataka
    Ogura, Takashi
    Makino, Shigeki
    Homma, Sakae
    Kondoh, Yasuhiro
    Saito, Aiko
    Ugai, Hiroyuki
    Gahlemann, Martina
    Takehara, Kazuhiko
    Azuma, Arata
    MODERN RHEUMATOLOGY, 2021, 31 (01) : 141 - 150
  • [37] Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): The SENSCIS Trial
    Distler, O.
    Highland, K. B.
    Gahlemann, M.
    Azuma, A.
    Fischer, A.
    Mayes, M.
    Raghu, G.
    Sauter, W.
    Girard, M.
    Alves, M.
    Clerisme-Beaty, E.
    Kuwana, M.
    Maher, T. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [38] SAFETY PROFILE OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE AND IDIOPATHIC PULMONARY FIBROSIS
    Highland, Kristin
    Distler, Oliver
    Gahlemann, Martina
    Azuma, Arata
    Fischer, Aryeh
    Mayes, Maureen
    Raghu, Ganesh
    Sauter, Wiebke
    Girard, Mannaig
    Kohlbrenner, Veronika
    Clerisme-Beaty, Emmanuelle
    Stowasser, Susanne
    Kuwana, Masataka
    Maher, Toby M.
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 200 - 200
  • [39] Nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD): the SENSCIS trial
    Prasse, A.
    Distler, O.
    Highland, K. B.
    Gahlemann, M.
    Azuma, A.
    Mayes, M. D.
    Raghu, G.
    Sauter, W.
    Girard, M.
    Alves, M.
    Clerisme-Beaty, E.
    Kuwana, M.
    Maher, T. M.
    PNEUMOLOGIE, 2020, 74 : S57 - S58
  • [40] Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
    Khanna, Dinesh
    Maher, Toby M.
    Volkmann, Elizabeth R.
    Allanore, Yannick
    Smith, Vanessa
    Assassi, Shervin
    Kreuter, Michael
    Hoffmann-Vold, Anna-Maria
    Kuwana, Masataka
    Stock, Christian
    Alves, Margarida
    Sambevski, Steven
    Denton, Christopher P.
    RMD OPEN, 2023, 9 (01):
12345